Astroglial atrophy in Alzheimer's disease

DOI:

[10.1007/s00424-019-02310-2](https://doi.org/10.1007/s00424-019-02310-2)

Document Version

Accepted author manuscript

[Link to publication record in Manchester Research Explorer](#)

Citation for published version (APA):

Verkhatsky, A., Rodrigues, J. J., Pivoriunas, A., Zorec, R., & Semyanov, A. (2019). Astroglial atrophy in Alzheimer's disease. *Pflugers Archiv European Journal of Physiology*, 471(10), 1247-1261. <https://doi.org/10.1007/s00424-019-02310-2>

Published in:

Pflugers Archiv European Journal of Physiology

Citing this paper

Please note that where the full-text provided on Manchester Research Explorer is the Author Accepted Manuscript or Proof version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version.

General rights

Copyright and moral rights for the publications made accessible in the Research Explorer are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Takedown policy

If you believe that this document breaches copyright please refer to the University of Manchester's Takedown Procedures [<http://man.ac.uk/04Y6Bo>] or contact uml.scholarlycommunications@manchester.ac.uk providing relevant details, so we can investigate your claim.

Astroglial atrophy in Alzheimer's disease

Alexei Verkhratsky^{1,2}, Jose Julio Rodrigues^{3,4}, Augustas Pivoriunas⁵, Robert Zorec^{6,7} &
Alexey Semyanov^{8,9}

¹Faculty of Biology, Medicine and Health, The University of Manchester,
Manchester, M13 9PT, UK;

²Achucarro Center for Neuroscience, IKERBASQUE, Basque Foundation for
Science, 48011 Bilbao, Spain;

³BioCruces Health Research Institute, IKERBASQUE, Basque Foundation for
Science 48011 Bilbao, Spain;

⁴Department of Neuroscience, The University of the Basque Country UPV/EHU,
Plaza de Cruces 12, 48903, Barakaldo, Bizkaia, Spain;

⁵Department of Stem Cell Biology, State Research Institute Centre for Innovative
Medicine, Santariškių street 5, LT-08406 Vilnius, Lithuania;

⁶University of Ljubljana, Medical Faculty, Institute of Pathophysiology, Laboratory of
Neuroendocrinology and Molecular Cell Physiology, Zaloska cesta 4; SI-1000,
Ljubljana, Slovenia;

⁷Celica, BIOMEDICAL, Technology Park 24, 1000 Ljubljana, Slovenia;

⁸Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of
Sciences, Miklukho-Maklaya street 16/10, Moscow, 117997, Russia;

⁹Sechenov First Moscow State Medical University, Moscow, Russia

Send all correspondence to:

Alexei Verkhratsky

The University of Manchester,

Oxford Road,

Manchester, M13 9PT, UK,

Telephone +44 (0)161-2757324,

e-mail: Alexej.Verkhatsky@manchester.ac.uk

Abstract

Astrocytes, a class of morphologically and functionally diverse primary homeostatic neuroglia, are key keepers of neural tissue homeostasis and fundamental contributors to brain defence in pathological contexts. Failure of astroglial support and defence facilitate the evolution of neurological diseases, which often results in aberrant synaptic transmission, neurodegeneration, and death of neurones. In Alzheimer's disease (AD) astrocytes undergo complex and multifaceted metamorphoses ranging from atrophy with loss of function to reactive astrogliosis with hypertrophy. Astroglial asthenia underlies reduced homeostatic support and neuroprotection that may account for impaired synaptic transmission and neuronal demise. Reactive astrogliosis which mainly develops in astrocytes associated with senile plaque is prominent at the early to moderate stages of AD manifested by mild cognitive impairment; down-regulation of astrogliosis (reflecting astroglial paralysis) is associated with late stages of the disease characterised by severe dementia. Cell-specific therapies aimed at boosting astroglial supportive and defensive capabilities and preventing astroglial paralysis may offer new directions in preventing, arresting or even curing AD-linked neurodegeneration.

Keywords: Astrocytes; Alzheimer's disease; Astroglial atrophy; Astrogliosis; Neurological diseases; Neurodegeneration

The epidemic of neurodegenerative diseases

The “epidemic” of neurodegenerative diseases prophesied by Robert Katzman in 1976 [63] spreads through the aging world population with little prospective for therapeutic containment. Despite remarkable progress in understanding the biochemistry and genetics of neurodegenerative processes the genesis and evolution of the majority of sporadic cases remain obscure, whereas pharmacological options remain symptomatic [122]. The ultimate outcome of neurodegeneration is neural cell death, brain atrophy and loss of brain function. A direct link between the decrease in the size (i.e., atrophy) of the brain tissue and decrease in cognitive capabilities (i.e., dementia) was suggested by Thomas de Willis at the end of 17th century [156]. Aberrant processing of proteins lies at the core of neurodegeneration; compromised synthesis/degradation or clearance of proteins results in accumulation of intra- or extracellular “toxic” proteins [55,118]. Despite the multitude of specific pathological pathways idiosyncratic for certain disease (e.g. β -amyloid accumulation and abnormal tau phosphorylation in Alzheimer’s disease (AD), α -synuclein accumulation in Parkinson’s disease or expression of mutant glial fibrillary acidic protein in Alexander disease) all neurodegenerative processes share a common pathological phenotype - they all trigger cell death and destroy connectivity in the neural networks.

Extracellular depositions of β -amyloid and intracellular accumulation of misphosphorylated tau protein (both processes are, most likely, interrelated with indications for tau pathology being driven by β -amyloid accumulation) are common histological denominators of the AD brains. Occurrence of these lesions, however, varies and there is no obvious correlation between their densities and the severity of dementia. The concept that tissue depositions of pathological material are causative for neurodegeneration was proposed by Oskar Fischer in 1907 [39,40]. The specific role for β -amyloid in the AD (the amyloid cascade hypothesis), remains, however, disputed [61,87,23]. Amyloid plaques occur in several neurological diseases; they were initially discovered by Paul Blocq and Gheorghe Marinescu in post-mortem brains from elderly patients with chronic epilepsy [11]; amyloid depositions populate posttraumatic nervous tissues, tissues infected with prions and brains affected by Parkinson’s or Huntington’s disease. Similarly, tau pathology is characteristic of fronto-temporal dementia and prion infection. In recent years the new concept of tau astrogliopathy had emerged, after the discovery of multiple pathological phenotypes of astrocytes infested with tau and related to specific forms of age-associated dementia [71]. Even acute sleep deprivation for a single night causes accumulation of β -amyloid, which is seemingly unrelated to any predisposition to AD [125].

It is, however, almost beyond dispute that the gross histopathological signs of AD became apparent at the late stages of the disease. The AD begins with prolonged (10 - 15 years) asymptomatic phase, when the overall cognitive function remains (almost) intact, although pathological changes begin to accumulate. It is most probable that from the very beginning AD-pathology affects synaptic transmission. There is a close correlation between synaptic alterations and cognitive impairments in AD patients, and these synaptic alterations are often considered to occur at the very early (pre-plaque) stages of the disease [31,135,55,89]. Nervous tissue, affected by AD is characterised by compromised synaptic connectivity and neuronal hyperexcitability, which are indicative of dyshomeostasis of ions and neurotransmitters [64,84,42,19]. The brain unwiring in AD is also manifested in white matter damage, which is

observed from the early stages and correlates with cognitive deficit [14]. Finally, the AD alters metabolic homeostasis of the nervous system; region-specific hypometabolism underlies AD-specific diagnostic phenotype used for FDG-PET diagnostics [59]. All these features indicate that AD (similarly to other neurodegenerative diseases) is a chronic homeostatic failure of the brain tissue, which, naturally, has to be associated with the failure of the homeostatic neuroglia.

Astrocytes provide homeostatic support and neuroprotection

The human brain evolved for over ~500 million years from the diffuse nervous system that appeared in the most primitive multicellular organisms. Evolution of nervous system progressed through an increase in the complexity of nervous tissue with a parallel increase in heterogeneity and specialisation of neural cells. Emergence of the central nervous system (CNS) with intricate synaptic web required sophisticated homeostatic support and thus much specialisation has occurred among neural cells, which were fundamentally divided into neurones, representing the executive arm and neuroglia, representing the housekeeping branch [111,143]. This division of responsibilities reflected the perfection of fast neuronal signalling (action potentials and synaptic transmission) that requires much energy and high level of protein expression with an inevitable loss of neuronal abilities to control tissue homeostasis. This task was transferred to neuroglia, which indeed is responsible for each and every homeostatic cascade operating in the nervous system. Conceptually, the term neuroglia covers cells responsible for homeostasis and defence of neural tissue. Neuroglia include several types of heterogeneous (both morphologically and functionally) cells of neural (astroglia, oligodendroglia, radial glia, NG2 cells, peripheral glia and enteric glia) and non-neural (microglia) origin (for overview and references see [67,139,48,144,147,66,129,69]).

The homeostasis of the CNS is mainly controlled by astrocytes, which are arguably the most diverse glial cells in the brain and in the spinal cord (Fig. 1). Astrocytes are defined as a class of neural cells, which sustain homeostasis and provide for neuroprotection and defence of the CNS tissue [144]. Astroglial cells account (depending on the brain region) for 20 - 40% of all neuroglial cells [140]. Astrocytes demonstrate remarkable adaptive plasticity that defines the functional maintenance of the CNS in development and ageing. Astrocytes maintain homeostasis of the CNS at all levels of organisation, from molecular to organ. Astroglia contribute to ionostasis of the CNS tissue by regulating fluxes of major ions; astrocytes control the turnover of major neurotransmitters through dedicated systems responsible for their uptake and for release of neurotransmitter precursors. Protoplasmic astrocytes divide (through the process known as tiling) the grey matter into relatively independent “neurovascular units”; the territorial domain of a single astrocyte (which overlaps in adult healthy brain with neighbouring astrocytes only at the level of very distal processes) integrates all neuronal elements and establishes direct link (through perivascular process and the endfoot) with capillaries [57,56,20,94]. The morphology of astrocytic processes defines their function. The processes can be classified into (i) astrocytic branches of several orders that contain organelles including endoplasmic reticulum Ca^{2+} stores, (ii) organelle-free perisynaptic leaflets that form astroglial cradle and (iii) endfeet tiling the blood vessels [68,101,144]. Astrocytic branches are responsible for amplification and propagation of Ca^{2+} signals within an astrocyte and possibly beyond [123]. Astrocytic perisynaptic leaflets are rich in glutamate transporters as well as

other homeostatic transporters and selectively approach dendritic spines, providing less coverage of presynaptic boutons and little coverage of dendritic shaft [44]. Endfeet intimately interact with cells of blood vessels supporting the blood-brain-barrier [130]. Using perivascular processes and endfeet astrocytes adjust local blood flow to the level of neuronal activity [90,165,131,38]. Astrocytes also act as an energy source (being the main if not the only producer of glycogen in the CNS) by providing neurones with lactate in an activity-dependent manner [104,80]. Furthermore, astrocytes synthesize glutamate *de novo* and supply neurones with glutamine, which is the main precursor for glutamate and GABA [54]. Astroglial leaflets cover central synapses by a synaptic cradle and control neuronal excitability and synaptic transmission in many ways from assisting synaptogenesis and synaptic maintenance to regulating extracellular concentration of ions and major neurotransmitters (such as glutamate, GABA monoamines and adenosine) [33,12,142,95,91]. Astrocytes are central elements for cellular homeostasis of the CNS being responsible for embryonic neurogenesis (which relies on radial glia) and for neurogenesis in the adult CNS (that occurs from radial astrocytes of the neurogenic niches, [36,13]). Finally, astrocytes are fundamental to brain defence through evolutionary conserved and complex programmes controlling reactive astrogliosis launched in response to polyaeithiological insults [103,128,151,102].

Principles and classification of astrogliopathology

Neurological disorders are, in essence, the failures of homeostasis, and neuroglia, being the homeostatic neural cells, are central to all types of neuropathologies. Whatever the aetiology, neurological diseases are, to a great extent, pathologies of neuroglia, the compromised function of which determines the survival or death of neurones thus defining the progression and the outcome of neurological diseases. The central role for neuroglia in neuropathology begun to be appreciated only recently when numerous experimental finding questioned the neuronocentric views [103,151,3,150,30,146,17,163,45,16,137,113].

The pathological potential of neuroglia was contemplated already by Rudolf Virchow who prophesied that “This very interstitial tissue of the brain and spinal marrow (*i.e. neuroglia* - authors) is one of the most frequent seats of morbid change” [153]. A fundamental contribution of neuroglia to neuropathology was also considered by Alois Alzheimer, Franz Nissl, Santiago Ramon-y-Cajal, Rio-Hortega and William Lloyd Andriezen, the latter reflecting that astrocytes “exhibit a morbid hypertrophy in pathological conditions” [2]. It is now the fact universally acknowledged that many neurological diseases are associated with the astrocytic hypertrophy and activation of microglia often referred to as reactive gliosis. For many years the reactive gliosis was considered as a general non-specific pathological reaction often regarded as a basis for neuroinflammation that is chiefly involved in exacerbating neuronal damage. This oversimplification is, however, very much detached from reality. The main function of neuroglia is the preservation of the nervous tissue, and as such multiple molecular cascades expressed in glia are genuinely neuroprotective. Astrocytes, for example, are primarily responsible for homeostasis of ions and neurotransmitters thus fencing against excitotoxic damage. Oligodendrocytes maintain axonal survival and the death of the former spells the imminent death on the latter. Microglia release multiple trophic factors ensuring neuronal survival. The reactive changes instigated by a brain lesion, represented by astrogliosis and microglial activation are therefore genuinely

survivalistic. These glial responses are complex and multistaged and are, as a rule, neuroprotective [103]. Being driven to an extreme by the severity of the insult, glial cells can assume the role of natural killer and contribute to the neural cell death, and yet even neurotoxicity of glia has, at its core, neuroprotective significance. Indeed, astroglial scar limits the area of damage and astrocytes and microglia surrounding the lesioned area through the releasing of neurotoxic factors rapidly exterminate pathologically affected cells thus contributing to the final clean-up (by phagocytic microglia and astrocytes [86,154]) and ultimate protection of the undamaged neural circuits lying outside of the damaged area. Finally, neuroglia is primarily responsible for the recovery of homeostasis in post-lesioned nervous tissue through promoting vascularization, reforming the blood-brain barrier, stimulating synaptogenesis and accomplishing re-myelination [128,151,1,18]. Conceptually, disruption of glial protection is fatal for the nervous system. All in all, neurones cannot function correctly or survive in the absence of glia, whereas glial cells can survive and operate in the presence of dead or dying neurones.

Pathological metamorphoses of astrocytes are complex, disease- and disease-stage specific and may change substantially in the course of pathological evolution. Conceptually, astrogliopathological phenotypes (see Glossary) are classified into three major groups: (i) reactive astrogliosis (ii) astrodegeneration with astroglial atrophy and loss of function and (iii) pathological remodelling [103,151]. The latter two groups of the non-reactive pathological transformation of astrocytes can be summarily identified as astrocytopathies to distinguish from reactive astrogliosis [37]. Astrocytes in the CNS are organised in the forms of syncytia confined to specific anatomical structures [46,47]. Astroglial syncytia are formed by intercellular gap junctions, which are composed from connexons (astrocytes express connexins 43, 30 and 26; with predominant presence of Cx43) permeable for ions and small (<1000 Da) molecules. Gap junctions participate in regulation of astrocyte electric properties [79], redistribution of K^+ ("spatial K^+ buffering" - [155]), diffusional transport of glucose [116] and propagation of Ca^{2+} waves [123,148]. Pathological changes in astrocytes frequently affect gap junctional connectivity within astroglial networks; which may define various aspects of neuropathological progression, for example, in epilepsy [9,106] or neurodegeneration [162].

Glossary of astrogliopathology:

Reactive astrogliosis, reactive astrocytes:

There is no universally agreed definition of the reactive astrogliosis [34]. We define reactive astrogliosis as an evolutionary conserved defensive response of astrocytes to pathological lesions caused by endo- or exogenous agents. Reactive astrogliosis leads to substantial changes in gene expression, resulting in a remodelling of astroglial morphology, biochemistry, and function, thus producing reactive astrocytes with multiple phenotypes. These reactive phenotypes are disease- and context- (for example ageing) specific, while reactive astrocytes could be either neuroprotective or neurotoxic, again depending on the pathology and severity of lesion. Morphology of reactive astrocytes is characterised by hypertrophy of somata and primary processes and significant up-regulation of intermediate filament proteins GFAP and vimentin (see [34,102,103,151] for further details).

Astroglial atrophy:

Defined as decrease in surface area and volume of astroglial morphological profiles; astroglial atrophy is manifested in specific diminution of peripheral and perisynaptic processes, which decrease synaptic coverage and synaptic homeostatic support. Astroglia atrophy has been reported in stress, depression, Alzheimer's disease and epilepsy [106,164,152,93].

Loss of function:

Decrease in expression or activity of astroglial homeostatic molecules or pathways (for example decrease in glutamate transporters activity), which reduce glial homeostatic support this instigating or exacerbating neuropathology.

Astroglial pathological remodelling:

Development of specific astroglial phenotype, which drives neuropathology. Examples are expression of mutant sporadically mutated GFAP in Alexander disease, which affect development of white matter and causes severe leicomalacia [82] or changes in glutamate/ammonium handling in hepatic encephalopathy, which affects neurotransmission and neuronal excitability thus causing psychotic symptoms and ultimately brain oedema [146].

Reactive astrogliosis is the most characterised response of astrocytes to pathological lesions [102]. Reactive astrogliosis can be defined as an evolutionary conserved defensive reprogramming of astroglia aimed at: (i) increased neuroprotection and trophic support of nervous tissue; (ii) isolation of the lesioned area; (iii) reconstruction of the damaged blood-brain barrier; and (iv) providing for post-lesion regeneration of brain circuits [102,103,128]. Astroglial reactivity is heterogeneous and disease-specific; reactive phenotypes may demonstrate both neuroprotective and neurotoxic features [76], although generally suppression of astroglial response exacerbates neuropathology [103].

Pathological remodelling of astrocytes reflects the emergence of abnormal astroglial phenotypes which either cause or drive neuropathological changes. Examples of pathological remodelling of astrocytes include for example leukodystrophies, such as Alexander disease, megalencephalic leukoencephalopathy with subcortical cysts or vanishing white matter syndrome. In all these pathologies pathologically modified astrocytes trigger white matter lesions [74]. Pathological remodelling of astrocytes was suggested as a contributing factor to mesial temporal lobe epilepsy. In this condition astrocytes acquire aberrant morphology, decrease gap junctional coupling and reduce K^+ buffering capability [9]. Yet another example of pathological remodelling of astrocytes is observed following infection with *Toxoplasma gondii*. Infiltration of astrocytes with *T. gondii* results in abnormal elevation of synthesis and release kynurenic acid that, through inhibition of NMDA and acetylcholine receptors, affects neurotransmission which may be linked to an increased risk of schizophrenia [120]. In AD astrocytes start to express GAD67 that also affects the balance of excitation and inhibition in the neuronal network [43,157].

Astrodegeneration appears as a decrease in astroglial density, is often accompanied by morphological atrophy, and invariably is associated with a loss of function, i.e. in decreased homeostatic, supportive and neuroprotective capabilities, which all constitute astroglial asthenia. Astroglial atrophy and asthenia are observed in a wide range of neurological disorders including neuropsychiatric diseases, addictive disorders, epilepsy and neurodegeneration. Reduction of astroglial numbers, astroglial morphological atrophy with decreased expression of GFAP as well as deficient glutamate uptake are detected in major neuropsychiatric diseases such as bipolar disease, major depression and schizophrenia [28,29,83,92,108-110,149,119]. Deficient astroglial support leads to abnormal neurotransmission and oxidative or excitotoxic stress which contribute to psychotic symptomatology. Similar morphological atrophy of astrocytes associated with decreased expression of glutamate transporters and deficient glutamate uptake were identified in the nucleus accumbens of cocaine-addicted rats [121]. Significant atrophy of astrocytes which may underlie aberrant K^+ buffering and glutamate homeostasis has been detected in experimental epilepsy [106]. Finally, as will be discussed below, astroglial atrophy is often seen in various neurodegenerative disorders.

Astrocytic atrophy may have a complex nature and affect astrocytic branches, leaflets and endfeet differently. Since these astrocytic processes have distinct functions, the effect on the neuronal network will be different. Atrophy of branches arguably affects astroglial Ca^{2+} signalling possibly inducing further morphological changes [132]. Perisynaptic leaflets are highly plastic and their changes accompany (or even drive) synaptic plasticity [105]. Hence, changes in perisynaptic leaflets can potentially contribute to pathological processes. Finally, atrophy of endfeet can potentially damage the neuron-glia-vascular unit, and affect the blood-brain barrier thus promoting neurodegeneration [126,133,78].

Morphological atrophy and functional impairment of astrocytes in neurodegenerative disorders

Degeneration of astroglia resulting in astroglial atrophy or death has been recently documented for several classes of neurological diseases associated with disruption in neural connectivity including excitotoxic neurodegeneration (Wernicke encephalopathy) chronic neurodegeneration (amyotrophic lateral sclerosis and Alzheimer's disease, thalamic dementia, fronto-temporal dementia) and psychiatric disorders such as schizophrenia, bipolar disorder and major depression, which all affect cognition. These dystrophic changes in astroglia often precede neurological symptoms or are key pathogenic factors.

In acute excitotoxic neurodegeneration of Wernicke type massive neuronal death results from functional astroglial degeneration manifested by down-regulation of expression of astroglial glutamate transporters. This compromises the ability of astrocytes to remove the excess of glutamate and to regulate glutamatergic transmission, which in turn results in severe excitotoxicity that underlies rapid development of severe dementia with prominent psychotic components [51,52].

In amyotrophic lateral sclerosis (ALS) astroglial degeneration precedes the development of neuronal death and clinical symptoms in transgenic mice model of the disease, in which cells express ALS-associated mutant human gene for superoxide

dismutase 1 (hSOD1^{G93A}). At the later stage of the disease neuronal death triggers reactive astrogliosis and yet atrophic astrocytes remain in the tissue [114,115,160,4]. Astrocytes selectively expressing SOD1 gene acquire vulnerability to glutamate excitotoxicity that may underlie their early degeneration. These degenerated astrocytes lose their ability to effectively control glutamate homeostasis through down-regulation of glutamate transporters expression that further exacerbates excitotoxicity and contributes to neuronal death [115]. Critically, specific silencing of SOD1 gene in astrocytes delays the progression of ALS symptoms in the mouse model [159].

Dystrophic changes in astrocytes have been observed in several types of neurodegenerative pathologies including fronto-temporal dementia and Pick's disease, some studies mentioned the direct correlation between the degree of glial atrophy and the severity of dementia [15,65]. In Huntington disease functional astrodegeneration is manifested by a decrease in expression of glutamate transporters and hence in exacerbated glutamate excitotoxicity [35]; similarly, astrocytes demonstrate deficits in K⁺ buffering [136]. In addition astrocytes in HD reduce production and release of glutathione and ascorbic acid that act as major scavengers of reactive oxygen species (ROS) in CNS; this further reduces astroglial neuroprotection.

Astroglial atrophy in Alzheimer's disease

Astroglial changes in AD are highly heterogeneous in different brain regions and are represented by both astrogliosis with astroglial hypertrophy and astroglial atrophy (Table 1 and [3,141,145]). When analysing longitudinal changes in expression of GFAP, a classic marker for astrogliosis, in a triple transgenic mouse model of AD a decrease in the morphological presence of GFAP profiles and an overall decrease in GFAP expression was observed in early pre-plaque stages of the disease (Fig. 3 and [73,97,98,161]). This decrease in GFAP-positive astroglial profiles appear very early (at ~ 1 month of age) in the entorhinal cortex, somewhat later (~ 3 months of age) in the prefrontal cortex and even later (~ 9 - 12 months) in the hippocampus. Morphological atrophy of astrocytes was also confirmed when analysing profiles labelled with antibodies against glutamine synthetase and protein s100b [98,161]; this staining reveals full extent of the cells (in contrast to GFAP which stains only primary processes). Emergence of senile plaques triggers astrogliosis, which, however, similarly differs between brain regions. In hippocampus β -amyloid depositions and β -amyloid plaques are surrounded by hypertrophic astrocytes [97], whereas little, if any, signs of astrogliosis were found in entorhinal and prefrontal cortices [73,161]. The GFAP-hypertrophic astrocytes in hippocampus were associated with β -amyloid depositions/plaques, while distantly to the plaques GFAP profiles remain atrophic [97]. Similar astroglial atrophy has been characterised in other models of AD including PDAPP-J20 transgenic mice, 5xTG-AD mice and Swiss 3 mouse AD model (Table 1, [58,107,32,8]). Astroglial atrophy was found not only in experimental model animals but in post-mortem tissues of patients with advanced (Braak V-VI) stages of the disease (Rodriguez and Verkhatsky, personal observations). Similarly, morphological atrophy was observed in astrocytes derived from induced pluripotent stem cells obtained from patients with both familial and sporadic forms of AD (Fig. 4; [60]). Enriched environment as well as physical activity prevents astroglial atrophy in an AD mouse model and ameliorates the symptoms, confirming the causal link between astrocyte remodelling and dementia [7,112].

It has to be noted, however, that animal models of AD only partially reproduce the human disease. For example, while 3xTG-AD mouse develops both plaque and tangle pathologies accompanied by some cognitive deficits, there is no massive neuronal loss which is a hallmark of AD progression in patients [10]. In this regard, new stem cell technologies that enable the generation of astrocytes from the disease-specific inducible pluripotent stem cells (iPSCs) [117], or by direct reprogramming of patient-specific fibroblasts [21] present a great promise. Although the field is still in its infancy, current technologies allow generation of relatively pure populations of cells exhibiting molecular and functional properties (electrophysiological signatures, generation of spontaneous calcium signals, glutamate uptake, support of synapse formation, etc.) similar to those of adult human astrocytes. The disease-specific astrocytes also recapitulate some important pathological aspects of AD. Thus, astrocytes derived from the familial AD and sporadic AD patients exhibited a less complex morphological appearance, decreased heterogeneity, overall atrophic profiles and abnormal localisation of key functional astroglial markers resembling changes occurring during glial paralysis at the early stages of the disease [60]. Astrocytes derived from familial AD patients also demonstrated increased β -amyloid production, deregulated Ca^{2+} homeostasis, altered cytokine release, increased ROS, decreased lactate production and compromised neuroprotection and neuronal support [85,96]. Astrocytes differentiated from isogenic APOE4 astrocytes were impaired in their ability to clear extracellular β -amyloid and displayed aberrant cholesterol accumulation [77]. A new human AD “triculture” model using neurones, astrocytes, and microglia in a 3D microfluidic platform has been successfully used to study neuroinflammatory responses [100]. These studies demonstrate the substantial potential of iPSC-based human astrocyte models to reveal the cellular mechanisms of AD. Undoubtedly, these technologies will improve our understanding of the molecular mechanisms controlling astroglial response and also help to develop astrocyte-specific therapies against AD.

Reactive astrogliosis in AD: does it always signal neuroinflammation?

Reactive astrogliosis is another hallmark of AD; increased expression of GFAP, vimentin or S100B protein as well as astroglial hypertrophy has been observed in post-mortem tissues from AD patients [6,49,81,88] as well as in brain samples of AD animal models [97,145,62,99]. In AD brains reactive astrocytes are mainly associated with senile plaques [72,97,99]. The idea that chronic neuroinflammation is directly responsible for the progression of idiopathic AD from the very early stages, and may even have an etiological significance, become quite popular in recent years [53]. It is also generally assumed that this chronic neuroinflammation results from activation of microglia and reactive astrogliosis. This statement however, needs clarification, as indeed reactive gliosis is far from being a straight pathological reaction ultimately resulting in damage to the brain tissue. The reactions of neuroglia to brain lesion (reflected by both reactive astrogliosis and activation of microglia) essentially represent a defensive response aimed at counteracting pathology and remodelling post-lesioned circuitry. Neither astrogliosis, nor microglial activation develops in all-or-none fashion; to the contrary they represent a continuum of phenotypic remodelling, fundamentally associated with neuroprotection. There are many stages and degrees in astrogliosis [103,127], and some of these are fully reversible. Limited brain lesions trigger astroglial hypertrophy and biochemical remodelling without

1 affecting microdomain organisation (anisomorphic astrogliosis); and only severe
 2 lesions disrupt astroglial territorial maps, arrange astrocytes in palisades and trigger
 3 scar formation [127,128]. Even the scar formation is in essence defensive and
 4 survivalistic reaction aimed at isolation of lesioned area from the healthy tissue.
 5 Likewise, activation of microglia is a multistage process with a multitude of activated
 6 phenotypes, many of which have a neuroprotective role [50,66]. In AD, both reactive
 7 astrogliosis and activation of microglia are directly associated with plaque formation;
 8 activated glial cells become elements of plaques. Importantly, activated astrocytes
 9 surrounding the plaques retain their domain organisation and do not express severe
 10 astrogliotic features; similarly, microglial cells do not turn in all-devouring
 11 macrophages, but retain intermediate activated phenotype. Suppression of astroglial
 12 reactivity, contrary to the inflammatory hypothesis, exacerbates β -amyloid load and
 13 reduces neuroprotection [72].
 14
 15

16 **Astroglial atrophy contributes to synaptic dysfunction and cognitive deficits**

17
 18
 19 Atrophic changes in astrocytes, characterised in several AD animal models as well as
 20 in stem-cells derived astrocytes appear as shrinkage of astroglial territories, with a
 21 decrease in astroglial coverage of synaptic contacts and other neuronal structures with
 22 the ultimate decline in astroglial homeostatic support. Astroglial atrophy and loss of
 23 function may contribute to early cognitive deficits through dwindling synaptic support
 24 and synaptic malfunction. Decreased astroglial synaptic coverage may also result in
 25 neurotransmitter spillover with subsequent hyperexcitability of neuronal networks
 26 often observed in neurodegeneration. In addition enhanced glutamate spillover may
 27 increase the recruitment of extrasynaptic NR2B subunit-containing NMDA receptors
 28 associated with long-term depression, LTD [5]. Thus decreased astroglial synaptic
 29 coverage with a consequent reduction in astroglial glutamate uptake may impair upon
 30 synaptic plasticity shifting it towards depression, which can in turn negatively affect
 31 memory [138,27].
 32
 33

34
 35
 36 Notably, K^+ clearance and glutamate uptake by astrocytes are tightly linked [75].
 37 During synaptic transmission most of K^+ entering the synaptic cleft is released
 38 through postsynaptic AMPA and NMDA receptors [24]. Accumulation of K^+ in the
 39 synaptic cleft depolarises presynaptic terminal causing activity-dependent facilitation
 40 of glutamate release [124,26]. Reduction of glutamate uptake can enhance recruitment
 41 of postsynaptic AMPA/NMDA receptors and causes further K^+ release. This
 42 instigates positive feedback, which can potentially lead to an uncontrolled increase in
 43 excitability of the synaptic network, excitotoxicity and neuronal death. In physiological
 44 conditions, these processes are tightly controlled by astroglial glutamate uptake and
 45 K^+ clearance. However, when glutamate uptake is impaired (due to the reduction of
 46 transporter expression or withdrawal of perisynaptic leaflets) the resulting vicious
 47 circle may contribute to neurodegeneration.
 48
 49

50
 51
 52 Furthermore limited astroglial support may instigate early extinction of synapses
 53 [166]. Dysfunctional synaptic transmission and loss of synapses are indeed the very
 54 first morphological changes in AD, which mount years before the occurrence of
 55 specific clinical presentation [134,25,70]. Astroglial asthenia may also suppress
 56 regenerative synaptogenesis; while the loss of astroglial transporters may contribute to
 57 excitotoxicity through impaired glutamate and K^+ buffering [166,152].
 58
 59
 60
 61
 62
 63
 64
 65

Failure of astroglial reactivity paves the way to dementia?

As has been alluded above, astrogliosis represents a powerful defensive program, which arguably contains various pathological processes including β -amyloid pathology and AD. Indeed there is compelling evidence demonstrating the neuroprotective potential of reactive astrocytes in AD. In the Tg2576 mice model (that bears APPSwe mutation) astrogliosis became prominent rather early and this correlates with the relatively slow development of AD. Furthermore, senile plaques in these animals resemble human β -amyloid deposits being represented by fleecy, granular, cored and diffused amyloid plaques [158]. In 3xTg-AD animals reactive astrocytes are positioned around senile plaques and close to perivascular β -amyloid deposits [97,98]. Conversely, in entorhinal and prefrontal cortices, the emergence of extracellular β -amyloid deposits does not initiate astrogliosis [73,161] which may reflect a failure of astroglial neuroprotection. This coincides with (and arguably underlines) high vulnerability of both regions to AD pathology; suggesting that paralysis of astroglial defence exacerbates AD-like pathology [141].

This notion also has been indirectly confirmed by the *in vivo* brain imaging of reactive astroglia in AD patients. Astrogliosis was assessed by positron-emission tomography detection of ^{11}C -deuterium-L-deprenyl (^{11}C -DED); deprenyl is a specific inhibitor of monoaminoxidase-B (MAO-B) localised predominantly in astrocytes. An increase in ^{11}C -DED signal hence is considered to reflect astroglial hypertrophy [41]. When using a multi-tracer PET detecting ^{11}C -PIB (marker of fibrillar β -amyloid), ^{18}F -FDG (marker of cerebral glucose metabolism) and ^{11}C -DED (marker of astrogliosis) the highest binding of ^{11}C -DED (which reflects prominent astrogliosis) was observed in patients with mild cognitive impairment (MCI) and high levels of fibrillar amyloid plaques in the brain (PIB+) reflecting prodromal AD [22]. The decrease in astroglial reactivity parallels the switch from MCI to full blown AD with senile dementia again demonstrating the neuroprotective role of astroglial remodelling [141].

Conclusions: the need for new astrocentric therapies?

In recent decades astrocytes emerged as a fundamental elements in pathophysiology of numerous neurological and neuropsychiatric diseases. Pathomorphological examination of astroglia has become a standard in describing the histology of the diseased brain. Pathophysiology of astroglia is a complex and multifactorial combination of degenerative and reactive remodelling, which can support neuroprotection or project neurotoxicity. Failure of astrocytes to support homeostasis of neural tissue and to protect this tissue against insults is arguably critical for determining the pathological evolution and ultimately neurological deficits. In the context of Alzheimer's disease astrocytes undergo atrophy with loss of function which may stipulate impairments of synaptic connectivity as well as contribute to neuronal death due to deficient neuroprotective support. At the same time, reactive astrocytes surround senile plaques in the AD brains; while initial stages of the disease are characterised by prominent astrogliosis. Exhaustion of astroglial defensive capacities and down-regulation of astrogliosis coincides with (and again may be instrumental for) the switch from mild cognitive impairment (characteristic for early to moderate AD stages) to senile dementia (which reflects late stages of the disease). Cell-specific therapies aimed at boosting astroglial supportive and defensive

capabilities and preventing astroglial paralysis may offer new directions in preventing, arresting or even curing AD-linked neurodegeneration.

Acknowledgments

AV and AS were supported by Volkswagen Stiftung research grant A115105; RZ by Slovenian Research Agency Research core funding #P3 310 and projects # J3 6790, # J3 9266 and # J3 7605. AS was supported by and COMFI grant 17-00-00412 (K) from RFBR; AV and AP were supported by the Global Grant measure (No. 09.3.3-LMT-K-712-01-0082).

References

1. Anderson MA, Burda JE, Ren Y, Ao Y, O'Shea TM, Kawaguchi R, Coppola G, Khakh BS, Deming TJ, Sofroniew MV (2016) Astrocyte scar formation aids central nervous system axon regeneration. *Nature* 532:195-200. doi:10.1038/nature17623
2. Andriezen WL (1893) The neuroglia elements of the brain. *Br Med J* 2:227-230
3. Arranz AM, De Strooper B (2019) The role of astroglia in Alzheimer's disease: pathophysiology and clinical implications. *Lancet Neurol* 18:406-414. doi:10.1016/S1474-4422(18)30490-3
4. Barbeito L (2018) Astrocyte-based cell therapy: new hope for amyotrophic lateral sclerosis patients? *Stem Cell Res Ther* 9:241. doi:10.1186/s13287-018-1006-y
5. Bartlett TE, Bannister NJ, Collett VJ, Dargan SL, Massey PV, Bortolotto ZA, Fitzjohn SM, Bashir ZI, Collingridge GL, Lodge D (2007) Differential roles of NR2A and NR2B-containing NMDA receptors in LTP and LTD in the CA1 region of two-week old rat hippocampus. *Neuropharmacology* 52:60-70. doi:10.1016/j.neuropharm.2006.07.013
6. Beach TG, McGeer EG (1988) Lamina-specific arrangement of astrocytic gliosis and senile plaques in Alzheimer's disease visual cortex. *Brain Res* 463:357-361
7. Beauquis J, Pavia P, Pomilio C, Vinuesa A, Podlutska N, Galvan V, Saravia F (2013) Environmental enrichment prevents astroglial pathological changes in the hippocampus of APP transgenic mice, model of Alzheimer's disease. *Exp Neurol* 239:28-37. doi:10.1016/j.expneurol.2012.09.009
8. Beauquis J, Vinuesa A, Pomilio C, Pavia P, Galvan V, Saravia F (2014) Neuronal and glial alterations, increased anxiety, and cognitive impairment before hippocampal amyloid deposition in PDAPP mice, model of Alzheimer's disease. *Hippocampus* 24:257-269. doi:10.1002/hipo.22219
9. Bedner P, Dupper A, Huttman K, Muller J, Herde MK, Dublin P, Deshpande T, Schramm J, Haussler U, Haas CA, Henneberger C, Theis M, Steinhäuser C (2015) Astrocyte uncoupling as a cause of human temporal lobe epilepsy. *Brain* 138:1208-1222. doi:10.1093/brain/awv067
10. Bilkei-Gorzo A (2014) Genetic mouse models of brain ageing and Alzheimer's disease. *Pharmacol Ther* 142:244-257. doi:10.1016/j.pharmthera.2013.12.009
11. Blocq P, Marinesco G (1892) Sur les lésions et la pathogenie de l'épilepsie dite essentielle. *La Semaine Médicale* 12:445-446
12. Boison D, Chen JF, Fredholm BB (2010) Adenosine signaling and function in glial cells. *Cell Death Differ* 17:1071-1082. doi:10.1038/cdd.2009.131
13. Bonzano S, Crisci I, Podlesny-Drabiniok A, Rolando C, Krezel W, Studer M, De Marchis S (2018) Neuron-Astroglia Cell Fate Decision in the Adult Mouse Hippocampal Neurogenic Niche Is Cell-Intrinsically Controlled by COUP-TFI In Vivo. *Cell Rep* 24:329-341. doi:10.1016/j.celrep.2018.06.044
14. Bozzali M, Padovani A, Caltagirone C, Borroni B (2011) Regional grey matter loss and brain disconnection across Alzheimer disease evolution. *Curr Med Chem* 18:2452-2458. doi:BSP/CMC/E-Pub/2011/175
15. Broe M, Kril J, Halliday GM (2004) Astrocytic degeneration relates to the severity of disease in frontotemporal dementia. *Brain* 127:2214-2220
16. Burda JE, Bernstein AM, Sofroniew MV (2016) Astrocyte roles in traumatic brain injury. *Exp Neurol* 275 Pt 3:305-315. doi:10.1016/j.expneurol.2015.03.020

17. Burda JE, Sofroniew MV (2014) Reactive gliosis and the multicellular response to CNS damage and disease. *Neuron* 81:229-248. doi:10.1016/j.neuron.2013.12.034
18. Burda JE, Sofroniew MV (2017) Seducing astrocytes to the dark side. *Cell Res* 27:726-727. doi:10.1038/cr.2017.37
19. Busche MA, Grienberger C, Keskin AD, Song B, Neumann U, Staufenbiel M, Forstl H, Konnerth A (2015) Decreased amyloid- β and increased neuronal hyperactivity by immunotherapy in Alzheimer's models. *Nat Neurosci* 18:1725-1727. doi:10.1038/nn.4163
20. Bushong EA, Martone ME, Jones YZ, Ellisman MH (2002) Protoplasmic astrocytes in CA1 stratum radiatum occupy separate anatomical domains. *J Neurosci* 22:183-192. doi:22/1/183
21. Caiazzo M, Giannelli S, Valente P, Lignani G, Carissimo A, Sessa A, Colasante G, Bartolomeo R, Massimino L, Ferroni S, Settembre C, Benfenati F, Broccoli V (2015) Direct conversion of fibroblasts into functional astrocytes by defined transcription factors. *Stem Cell Reports* 4:25-36. doi:10.1016/j.stemcr.2014.12.002
22. Carter SF, Scholl M, Almkvist O, Wall A, Engler H, Langstrom B, Nordberg A (2012) Evidence for astrogliosis in prodromal Alzheimer disease provided by ^{11}C -deuterium-L-deprenyl: a multitracers PET paradigm combining ^{11}C -Pittsburgh compound B and ^{18}F -FDG. *J Nucl Med* 53:37-46. doi:10.2967/jnumed.110.087031
23. Castellani RJ, Smith MA (2011) Compounding artefacts with uncertainty, and an amyloid cascade hypothesis that is 'too big to fail'. *J Pathol* 224:147-152. doi:10.1002/path.2885
24. Cheung G, Sibille J, Zapata J, Rouach N (2015) Activity-Dependent Plasticity of Astroglial Potassium and Glutamate Clearance. *Neural Plast* 2015:109106. doi:10.1155/2015/109106
25. Coleman P, Federoff H, Kurlan R (2004) A focus on the synapse for neuroprotection in Alzheimer disease and other dementias. *Neurology* 63:1155-1162
26. Contini D, Price SD, Art JJ (2017) Accumulation of K^+ in the synaptic cleft modulates activity by influencing both vestibular hair cell and calyx afferent in the turtle. *J Physiol* 595:777-803. doi:10.1113/JP273060
27. Cui Z, Feng R, Jacobs S, Duan Y, Wang H, Cao X, Tsien JZ (2013) Increased NR2A:NR2B ratio compresses long-term depression range and constrains long-term memory. *Sci Rep* 3:1036. doi:10.1038/srep01036
28. Czeh B, Di Benedetto B (2013) Antidepressants act directly on astrocytes: evidences and functional consequences. *Eur Neuropsychopharmacol* 23:171-185. doi:10.1016/j.euroneuro.2012.04.017
29. Czeh B, Nagy SA (2018) Clinical Findings Documenting Cellular and Molecular Abnormalities of Glia in Depressive Disorders. *Front Mol Neurosci* 11:56. doi:10.3389/fnmol.2018.00056
30. De Keyser J, Mostert JP, Koch MW (2008) Dysfunctional astrocytes as key players in the pathogenesis of central nervous system disorders. *J Neurol Sci* 267:3-16. doi:10.1016/j.jns.2007.08.044
31. DeKosky ST, Scheff SW (1990) Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. *Ann Neurol* 27:457-464. doi:10.1002/ana.410270502

32. Diniz LP, Tortelli V, Matias I, Morgado J, Bergamo Araujo AP, Melo HM, Seixas da Silva GS, Alves-Leon SV, de Souza JM, Ferreira ST, De Felice FG, Gomes FCA (2017) Astrocyte Transforming Growth Factor β 1 Protects Synapses against Abeta Oligomers in Alzheimer's Disease Model. *J Neurosci* 37:6797-6809. doi:10.1523/JNEUROSCI.3351-16.2017
33. Eroglu C, Barres BA (2010) Regulation of synaptic connectivity by glia. *Nature* 468:223-231. doi:10.1038/nature09612
34. Escartin C, Guillemaud O, Carrillo-de Sauvage M-A (2019) Questions and (some) answers on reactive astrocytes. *Glia* E-pub ahead of print. doi:10.1002/glia.23687
35. Estrada-Sánchez AM, Rebec GV (2012) Corticostriatal dysfunction and glutamate transporter 1 (GLT1) in Huntington's disease: Interactions between neurons and astrocytes. *Basal Ganglia* 2:57-66
36. Falk S, Gotz M (2017) Glial control of neurogenesis. *Curr Opin Neurobiol* 47:188-195. doi:10.1016/j.conb.2017.10.025
37. Ferrer I (2017) Diversity of astroglial responses across human neurodegenerative disorders and brain aging. *Brain Pathol* 27:645-674. doi:10.1111/bpa.12538
38. Filosa JA, Morrison HW, Iddings JA, Du W, Kim KJ (2016) Beyond neurovascular coupling, role of astrocytes in the regulation of vascular tone. *Neuroscience* 323:96-109. doi:10.1016/j.neuroscience.2015.03.064
39. Fischer O (1907) Miliare Nekrosen mit drusigen Wucherungen der Neurofibrillen, eine regelmässige Veränderung der Hirnrinde bei seniler Demenz. *Monatsschr Psychiatr Neurol* 22:361-372
40. Fischer O (1910) Die presbyofrene Demenz, deren anatomischen Grundlage und klinische Abgrenzung. *Z Ges Neurol Psychiatr* 3:371-471
41. Fowler JS, Volkow ND, Wang GJ, Logan J, Pappas N, Shea C, MacGregor R (1997) Age-related increases in brain monoamine oxidase B in living healthy human subjects. *Neurobiol Aging* 18:431-435
42. Frazzini V, Guarnieri S, Bomba M, Navarra R, Morabito C, Mariggio MA, Sensi SL (2016) Altered $K_v2.1$ functioning promotes increased excitability in hippocampal neurons of an Alzheimer's disease mouse model. *Cell Death Dis* 7:e2100. doi:10.1038/cddis.2016.18
43. Garaschuk O, Verkhratsky A (2019) GABAergic astrocytes in Alzheimer's disease. *Aging (Albany NY)* 11:1602-1604. doi:10.18632/aging.101870
44. Gavrilov N, Golyagina I, Brazhe A, Scimemi A, Turlapov V, Semyanov A (2018) Astrocytic Coverage of Dendritic Spines, Dendritic Shafts, and Axonal Boutons in Hippocampal Neuropil. *Front Cell Neurosci* 12:248. doi:10.3389/fncel.2018.00248
45. Giaume C, Kirchhoff F, Matute C, Reichenbach A, Verkhratsky A (2007) Glia: the fulcrum of brain diseases. *Cell Death Differ* 14:1324-1335. doi:10.1038/sj.cdd.4402144
46. Giaume C, Koulakoff A, Roux L, Holcman D, Rouach N (2010) Astroglial networks: a step further in neuroglial and gliovascular interactions. *Nat Rev Neurosci* 11:87-99. doi:10.1038/nrn2757
47. Giaume C, Liu X (2012) From a glial syncytium to a more restricted and specific glial networking. *J Physiol Paris* 106:34-39. doi:10.1016/j.jphysparis.2011.09.001
48. Ginhoux F, Garel S (2018) The mysterious origins of microglia. *Nat Neurosci* 21:897-899. doi:10.1038/s41593-018-0176-3

49. Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, White CL, 3rd, Araoz C (1989) Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. *Proc Natl Acad Sci U S A* 86:7611-7615
50. Hanisch UK, Kettenmann H (2007) Microglia: active sensor and versatile effector cells in the normal and pathologic brain. *Nat Neurosci* 10:1387-1394. doi:10.1038/nn1997
51. Hazell AS (2009) Astrocytes are a major target in thiamine deficiency and Wernicke's encephalopathy. *Neurochem Int* 55:129-135
52. Hazell AS, Sheedy D, Oanea R, Aghourian M, Sun S, Jung JY, Wang D, Wang C (2009) Loss of astrocytic glutamate transporters in Wernicke encephalopathy. *Glia* 58:148-156
53. Herrup K (2010) Reimagining Alzheimer's disease--an age-based hypothesis. *J Neurosci* 30:16755-16762. doi:10.1523/JNEUROSCI.4521-10.2010
54. Hertz L, Zielke HR (2004) Astrocytic control of glutamatergic activity: astrocytes as stars of the show. *Trends Neurosci* 27:735-743. doi:10.1016/j.tins.2004.10.008
55. Huang Y, Mucke L (2012) Alzheimer mechanisms and therapeutic strategies. *Cell* 148:1204-1222. doi:10.1016/j.cell.2012.02.040
56. Iadecola C (2004) Neurovascular regulation in the normal brain and in Alzheimer's disease. *Nat Rev Neurosci* 5:347-360. doi:10.1038/nrn1387
57. Iadecola C, Nedergaard M (2007) Glial regulation of the cerebral microvasculature. *Nat Neurosci* 10:1369-1376. doi:10.1038/nn2003
58. Iram T, Trudler D, Kain D, Kanner S, Galron R, Vassar R, Barzilai A, Blinder P, Fishelson Z, Frenkel D (2016) Astrocytes from old Alzheimer's disease mice are impaired in Abeta uptake and in neuroprotection. *Neurobiol Dis* 96:84-94. doi:10.1016/j.nbd.2016.08.001
59. Johnson KA, Fox NC, Sperling RA, Klunk WE (2012) Brain imaging in Alzheimer disease. *Cold Spring Harb Perspect Med* 2:a006213. doi:10.1101/cshperspect.a006213
60. Jones VC, Atkinson-Dell R, Verkhratsky A, Mohamet L (2017) Aberrant iPSC-derived human astrocytes in Alzheimer's disease. *Cell Death Dis* 8:e2696. doi:10.1038/cddis.2017.89
61. Kametani F, Hasegawa M (2018) Reconsideration of Amyloid Hypothesis and Tau Hypothesis in Alzheimer's Disease. *Front Neurosci* 12:25. doi:10.3389/fnins.2018.00025
62. Kamphuis W, Kooijman L, Orre M, Stassen O, Pekny M, Hol EM (2015) GFAP and vimentin deficiency alters gene expression in astrocytes and microglia in wild-type mice and changes the transcriptional response of reactive glia in mouse model for Alzheimer's disease. *Glia* 63:1036-1056. doi:10.1002/glia.22800
63. Katzman R (1976) Editorial: The prevalence and malignancy of Alzheimer disease. A major killer. *Arch Neurol* 33:217-218
64. Kazim SF, Chuang SC, Zhao W, Wong RK, Bianchi R, Iqbal K (2017) Early-Onset Network Hyperexcitability in Presymptomatic Alzheimer's Disease Transgenic Mice Is Suppressed by Passive Immunization with Anti-Human APP/Abeta Antibody and by mGluR5 Blockade. *Front Aging Neurosci* 9:71. doi:10.3389/fnagi.2017.00071

65. Kersaitis C, Halliday GM, Kril JJ (2004) Regional and cellular pathology in frontotemporal dementia: relationship to stage of disease in cases with and without Pick bodies. *Acta Neuropathol* 108:515-523
66. Kettenmann H, Hanisch UK, Noda M, Verkhratsky A (2011) Physiology of microglia. *Physiol Rev* 91:461-553. doi:10.1152/physrev.00011.2010
67. Kettenmann H, Ransom BR (eds) (2013) *Neuroglia*. Oxford University Press, Oxford
68. Khakh BS, Sofroniew MV (2015) Diversity of astrocyte functions and phenotypes in neural circuits. *Nat Neurosci* 18:942-952. doi:10.1038/nn.4043
69. Kimelberg HK, Nedergaard M (2010) Functions of astrocytes and their potential as therapeutic targets. *Neurotherapeutics* 7:338-353. doi:10.1016/j.nurt.2010.07.006
70. Koffie RM, Hyman BT, Spires-Jones TL (2011) Alzheimer's disease: synapses gone cold. *Mol Neurodegener* 6:63. doi:10.1186/1750-1326-6-63
71. Kovacs GG, Ferrer I, Grinberg LT, Alafuzoff I, Attems J, Budka H, Cairns NJ, Crary JF, Duyckaerts C, Ghetti B, Halliday GM, Ironside JW, Love S, Mackenzie IR, Munoz DG, Murray ME, Nelson PT, Takahashi H, Trojanowski JQ, Ansorge O, Arzberger T, Baborie A, Beach TG, Bieniek KF, Bigio EH, Bodi I, Dugger BN, Feany M, Gelpi E, Gentleman SM, Giaccone G, Hatanpaa KJ, Heale R, Hof PR, Hofer M, Hortobagyi T, Jellinger K, Jicha GA, Ince P, Kofler J, Kovari E, Kril JJ, Mann DM, Matej R, McKee AC, McLean C, Milenkovic I, Montine TJ, Murayama S, Lee EB, Rahimi J, Rodriguez RD, Rozemuller A, Schneider JA, Schultz C, Seeley W, Seilhean D, Smith C, Tagliavini F, Takao M, Thal DR, Toledo JB, Tolnay M, Troncoso JC, Vinters HV, Weis S, Wharton SB, White CL, 3rd, Wisniewski T, Woulfe JM, Yamada M, Dickson DW (2016) Aging-related tau astroglialopathy (ARTAG): harmonized evaluation strategy. *Acta Neuropathol* 131:87-102. doi:10.1007/s00401-015-1509-x
72. Kraft AW, Hu X, Yoon H, Yan P, Xiao Q, Wang Y, Gil SC, Brown J, Wilhelmsson U, Restivo JL, Cirrito JR, Holtzman DM, Kim J, Pekny M, Lee JM (2013) Attenuating astrocyte activation accelerates plaque pathogenesis in APP/PS1 mice. *FASEB J* 27:187-198. doi:10.1096/fj.12-208660
73. Kulijewicz-Nawrot M, Verkhratsky A, Chvatal A, Sykova E, Rodriguez JJ (2012) Astrocytic cytoskeletal atrophy in the medial prefrontal cortex of a triple transgenic mouse model of Alzheimer's disease. *J Anat* 221:252-262. doi:10.1111/j.1469-7580.2012.01536.x
74. Lanciotti A, Brignone MS, Bertini E, Petrucci TC, Aloisi F, Ambrosini E (2013) Astrocytes: Emerging stars in leukodystrophy pathogenesis. *Transl Neurosci* 4. doi:10.2478/s13380-013-0118-1
75. Lebedeva A, Plata A, Nosova O, Tyurikova O, Semyanov A (2018) Activity-dependent changes in transporter and potassium currents in hippocampal astrocytes. *Brain Res Bull* 136:37-43. doi:10.1016/j.brainresbull.2017.08.015
76. Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, Bennett ML, Munch AE, Chung WS, Peterson TC, Wilton DK, Frouin A, Napier BA, Panicker N, Kumar M, Buckwalter MS, Rowitch DH, Dawson VL, Dawson TM, Stevens B, Barres BA (2017) Neurotoxic reactive astrocytes are induced by activated microglia. *Nature* 541:481-487. doi:10.1038/nature21029
77. Lin YT, Seo J, Gao F, Feldman HM, Wen HL, Penney J, Cam HP, Gjoneska E, Raja WK, Cheng J, Rueda R, Kritskiy O, Abdurrob F, Peng Z, Milo B, Yu CJ,

- Elmsaouri S, Dey D, Ko T, Yankner BA, Tsai LH (2018) APOE4 Causes Widespread Molecular and Cellular Alterations Associated with Alzheimer's Disease Phenotypes in Human iPSC-Derived Brain Cell Types. *Neuron* 98:1141-1154 e1147. doi:10.1016/j.neuron.2018.05.008
78. Liu CY, Yang Y, Ju WN, Wang X, Zhang HL (2018) Emerging Roles of Astrocytes in Neuro-Vascular Unit and the Tripartite Synapse With Emphasis on Reactive Gliosis in the Context of Alzheimer's Disease. *Front Cell Neurosci* 12:193. doi:10.3389/fncel.2018.00193
79. Ma B, Buckalew R, Du Y, Kiyoshi CM, Alford CC, Wang W, McTigue DM, Enyeart JJ, Terman D, Zhou M (2016) Gap junction coupling confers isopotentiality on astrocyte syncytium. *Glia* 64:214-226. doi:10.1002/glia.22924
80. Magistretti PJ, Allaman I (2018) Lactate in the brain: from metabolic end-product to signalling molecule. *Nat Rev Neurosci* 19:235-249. doi:10.1038/nrn.2018.19
81. Meda L, Baron P, Scarlato G (2001) Glial activation in Alzheimer's disease: the role of Aβ and its associated proteins. *Neurobiol Aging* 22:885-893
82. Messing A, Brenner M, Feany MB, Nedergaard M, Goldman JE (2012) Alzheimer disease. *J Neurosci* 32:5017-5023. doi:10.1523/JNEUROSCI.5384-11.2012
83. Miguel-Hidalgo JJ, Waltzer R, Whittom AA, Austin MC, Rajkowska G, Stockmeier CA (2010) Glial and glutamatergic markers in depression, alcoholism, and their comorbidity. *J Affect Disord* 127:230-240. doi:10.1016/j.jad.2010.06.003
84. Minkeviciene R, Rheims S, Dobszay MB, Zilberter M, Hartikainen J, Fulop L, Penke B, Zilberter Y, Harkany T, Pitkanen A, Tanila H (2009) Amyloid β-induced neuronal hyperexcitability triggers progressive epilepsy. *J Neurosci* 29:3453-3462. doi:10.1523/JNEUROSCI.5215-08.2009
85. Mohamet L, Jones VC, Dayanithi G, Verkhatsky A (2018) Pathological human astroglia in Alzheimer's disease: opening new horizons with stem cell technology. *Future Neurology* 13:87 - 99. doi:10.2217/fnl-2017-0029
86. Morizawa YM, Hirayama Y, Ohno N, Shibata S, Shigetomi E, Sui Y, Nabekura J, Sato K, Okajima F, Takebayashi H, Okano H, Koizumi S (2017) Reactive astrocytes function as phagocytes after brain ischemia via ABCA1-mediated pathway. *Nat Commun* 8:28. doi:10.1038/s41467-017-00037-1
87. Morris GP, Clark IA, Vissel B (2014) Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease. *Acta Neuropathol Commun* 2:135. doi:10.1186/s40478-014-0135-5
88. Mrak RE, Griffin WS (2005) Glia and their cytokines in progression of neurodegeneration. *Neurobiol Aging* 26:349-354
89. Mucke L, Selkoe DJ (2012) Neurotoxicity of amyloid β-Protein: synaptic and network dysfunction. *Cold Spring Harb Perspect Med* 2:a006338
90. Mulligan SJ, MacVicar BA (2004) Calcium transients in astrocyte endfeet cause cerebrovascular constrictions. *Nature* 431:195-199. doi:10.1038/nature02827
91. Nagai J, Rajbhandari AK, Gangwani MR, Hachisuka A, Coppola G, Masmanidis SC, Fanselow MS, Khakh BS (2019) Hyperactivity with Disrupted Attention by Activation of an Astrocyte Synaptogenic Cue. *Cell* 177:1280-1292 e1220. doi:10.1016/j.cell.2019.03.019
92. Nagy C, Torres-Platas SG, Mechawar N, Turecki G (2017) Repression of Astrocytic Connexins in Cortical and Subcortical Brain Regions and

- Prefrontal Enrichment of H3K9me3 in Depression and Suicide. *Int J Neuropsychopharmacol* 20:50-57. doi:10.1093/ijnp/pyw071
93. Naskar S, Chattarji S (2019) Stress Elicits Contrasting Effects on the Structure and Number of Astrocytes in the Amygdala versus Hippocampus. *eNeuro* 6: e0338. doi:10.1523/ENEURO.0338-18.2019
 94. Nedergaard M, Ransom B, Goldman SA (2003) New roles for astrocytes: redefining the functional architecture of the brain. *Trends Neurosci* 26:523-530
 95. Nedergaard M, Verkhratsky A (2012) Artifact versus reality--how astrocytes contribute to synaptic events. *Glia* 60:1013-1023. doi:10.1002/glia.22288
 96. Oksanen M, Petersen AJ, Naumenko N, Puttonen K, Lehtonen S, Gubert Olive M, Shakirzyanova A, Leskela S, Sarajarvi T, Viitanen M, Rinne JO, Hiltunen M, Haapasalo A, Giniatullin R, Tavi P, Zhang SC, Kanninen KM, Hamalainen RH, Koistinaho J (2017) PSEN1 Mutant iPSC-Derived Model Reveals Severe Astrocyte Pathology in Alzheimer's Disease. *Stem Cell Reports* 9:1885-1897. doi:10.1016/j.stemcr.2017.10.016
 97. Olabarria M, Noristani HN, Verkhratsky A, Rodriguez JJ (2010) Concomitant astroglial atrophy and astrogliosis in a triple transgenic animal model of Alzheimer's disease. *Glia* 58:831-838. doi:10.1002/glia.20967
 98. Olabarria M, Noristani HN, Verkhratsky A, Rodriguez JJ (2011) Age-dependent decrease in glutamine synthetase expression in the hippocampal astroglia of the triple transgenic Alzheimer's disease mouse model: mechanism for deficient glutamatergic transmission? *Mol Neurodegener* 6:55. doi:10.1186/1750-1326-6-55
 99. Osborn LM, Kamphuis W, Wadman WJ, Hol EM (2016) Astrogliosis: An integral player in the pathogenesis of Alzheimer's disease. *Prog Neurobiol* 144:121-141. doi:10.1016/j.pneurobio.2016.01.001
 100. Park J, Wetzel I, Marriott I, Dreau D, D'Avanzo C, Kim DY, Tanzi RE, Cho H (2018) A 3D human triculture system modeling neurodegeneration and neuroinflammation in Alzheimer's disease. *Nat Neurosci* 21:941-951. doi:10.1038/s41593-018-0175-4
 101. Patrushev I, Gavrilov N, Turlapov V, Semyanov A (2013) Subcellular location of astrocytic calcium stores favors extrasynaptic neuron-astrocyte communication. *Cell Calcium* 54:343-349. doi:10.1016/j.ceca.2013.08.003
 102. Pekny M, Pekna M (2014) Astrocyte reactivity and reactive astrogliosis: costs and benefits. *Physiol Rev* 94:1077-1098. doi:10.1152/physrev.00041.2013
 103. Pekny M, Pekna M, Messing A, Steinhäuser C, Lee JM, Parpura V, Hol EM, Sofroniew MV, Verkhratsky A (2016) Astrocytes: a central element in neurological diseases. *Acta Neuropathol* 131:323-345. doi:10.1007/s00401-015-1513-1
 104. Pellerin L, Magistretti PJ (2012) Sweet sixteen for ANLS. *J Cereb Blood Flow Metab* 32:1152-1166. doi:10.1038/jcbfm.2011.149
 105. Perez-Alvarez A, Navarrete M, Covelo A, Martin ED, Araque A (2014) Structural and functional plasticity of astrocyte processes and dendritic spine interactions. *J Neurosci* 34:12738-12744. doi:10.1523/JNEUROSCI.2401-14.2014
 106. Plata A, Lebedeva A, Denisov P, Nosova O, Postnikova TY, Pimashkin A, Brazhe A, Zaitsev AV, Rusakov DA, Semyanov A (2018) Astrocytic Atrophy Following Status Epilepticus Parallels Reduced Ca²⁺ Activity and Impaired

- Synaptic Plasticity in the Rat Hippocampus. *Front Mol Neurosci* 11:215. doi:10.3389/fnmol.2018.00215
107. Polis B, Srikanth KD, Elliott E, Gil-Henn H, Samson AO (2018) L-Norvaline Reverses Cognitive Decline and Synaptic Loss in a Murine Model of Alzheimer's Disease. *Neurotherapeutics* 15:1036-1054. doi:10.1007/s13311-018-0669-5
 108. Rajkowska G, Legutko B, Moulana M, Syed M, Romero DG, Stockmeier CA, Miguel-Hidalgo JJ (2018) Astrocyte pathology in the ventral prefrontal white matter in depression. *J Psychiatr Res* 102:150-158. doi:10.1016/j.jpsychires.2018.04.005
 109. Rajkowska G, Miguel-Hidalgo JJ (2007) Gliogenesis and glial pathology in depression. *CNS Neurol Disord Drug Targets* 6:219-233
 110. Rajkowska G, Stockmeier CA (2013) Astrocyte pathology in major depressive disorder: insights from human postmortem brain tissue. *Curr Drug Targets* 14:1225-1236
 111. Reichenbach A, Pannicke T (2008) Neuroscience. A new glance at glia. *Science* 322:693-694. doi:10.1126/science.1166197
 112. Rodriguez JJ, Terzieva S, Olabarria M, Lanza RG, Verkhratsky A (2013) Enriched environment and physical activity reverse astroglial degeneration in the hippocampus of AD transgenic mice. *Cell Death Dis* 4:e678. doi:10.1038/cddis.2013.194
 113. Rossi D (2015) Astrocyte physiopathology: At the crossroads of intercellular networking, inflammation and cell death. *Prog Neurobiol* 130:86-120. doi:10.1016/j.pneurobio.2015.04.003
 114. Rossi D, Brambilla L, Valori CF, Roncoroni C, Crugnola A, Yokota T, Bredesen DE, Volterra A (2008) Focal degeneration of astrocytes in amyotrophic lateral sclerosis. *Cell Death Differ* 15:1691-1700
 115. Rossi D, Volterra A (2009) Astrocytic dysfunction: Insights on the role in neurodegeneration. *Brain Res Bull* 80:224-232
 116. Rouach N, Koulakoff A, Abudara V, Willecke K, Giaume C (2008) Astroglial metabolic networks sustain hippocampal synaptic transmission. *Science* 322:1551-1555. doi:10.1126/science.1164022
 117. Rowland HA, Hooper NM, Kellett KAB (2018) Modelling Sporadic Alzheimer's Disease Using Induced Pluripotent Stem Cells. *Neurochem Res* 43:2179-2198. doi:10.1007/s11064-018-2663-z
 118. Rubinsztein DC (2006) The roles of intracellular protein-degradation pathways in neurodegeneration. *Nature* 443:780-786. doi:10.1038/nature05291
 119. Sanacora G, Banasr M (2013) From pathophysiology to novel antidepressant drugs: glial contributions to the pathology and treatment of mood disorders. *Biol Psychiatry* 73:1172-1179. doi:10.1016/j.biopsych.2013.03.032
 120. Schwarcz R, Hunter CA (2007) Toxoplasma gondii and schizophrenia: linkage through astrocyte-derived kynurenic acid? *Schizophr Bull* 33:652-653. doi:10.1093/schbul/sbm030
 121. Scofield MD, Li H, Siemsen BM, Healey KL, Tran PK, Woronoff N, Boger HA, Kalivas PW, Reissner KJ (2016) Cocaine self-administration and extinction leads to reduced glial fibrillary acidic protein expression and morphometric features of astrocytes in the nucleus accumbens core. *Biol Psychiatry* 80:207-215. doi:10.1016/j.biopsych.2015.12.022
 122. Selkoe D, Mandelkow E, Holtzman D (2012) Deciphering Alzheimer disease. *Cold Spring Harb Perspect Med* 2:a011460. doi:10.1101/cshperspect.a011460

123. Semyanov A (2019) Spatiotemporal pattern of calcium activity in astrocytic network. *Cell Calcium* 78:15-25. doi:10.1016/j.ceca.2018.12.007
124. Shih PY, Savtchenko LP, Kamasawa N, Dembitskaya Y, McHugh TJ, Rusakov DA, Shigemoto R, Semyanov A (2013) Retrograde synaptic signaling mediated by K⁺ efflux through postsynaptic NMDA receptors. *Cell Rep* 5:941-951. doi:10.1016/j.celrep.2013.10.026
125. Shokri-Kojori E, Wang GJ, Wiers CE, Demiral SB, Guo M, Kim SW, Lindgren E, Ramirez V, Zehra A, Freeman C, Miller G, Manza P, Srivastava T, De Santi S, Tomasi D, Benveniste H, Volkow ND (2018) β -Amyloid accumulation in the human brain after one night of sleep deprivation. *Proc Natl Acad Sci U S A* 115:4483-4488. doi:10.1073/pnas.1721694115
126. Simon MJ, Wang MX, Murchison CF, Roesse NE, Boespflug EL, Woltjer RL, Iliff JJ (2018) Transcriptional network analysis of human astrocytic endfoot genes reveals region-specific associations with dementia status and tau pathology. *Sci Rep* 8:12389. doi:10.1038/s41598-018-30779-x
127. Sofroniew MV (2009) Molecular dissection of reactive astrogliosis and glial scar formation. *Trends Neurosci* 32:638-647. doi:10.1016/j.tins.2009.08.002
128. Sofroniew MV (2014) Astrogliosis. *Cold Spring Harb Perspect Biol* 7:a020420. doi:10.1101/cshperspect.a020420
129. Sofroniew MV, Vinters HV (2010) Astrocytes: biology and pathology. *Acta Neuropathol* 119:7-35. doi:10.1007/s00401-009-0619-8
130. Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zlokovic BV (2019) Blood-Brain Barrier: From Physiology to Disease and Back. *Physiol Rev* 99:21-78. doi:10.1152/physrev.00050.2017
131. Takano T, Tian GF, Peng W, Lou N, Libionka W, Han X, Nedergaard M (2006) Astrocyte-mediated control of cerebral blood flow. *Nat Neurosci* 9:260-267. doi:10.1038/nn1623
132. Tanaka M, Shih PY, Gomi H, Yoshida T, Nakai J, Ando R, Furuichi T, Mikoshiba K, Semyanov A, Itohara S (2013) Astrocytic Ca²⁺ signals are required for the functional integrity of tripartite synapses. *Mol Brain* 6:6. doi:10.1186/1756-6606-6-6
133. Tarantini S, Tran CHT, Gordon GR, Ungvari Z, Csiszar A (2017) Impaired neurovascular coupling in aging and Alzheimer's disease: Contribution of astrocyte dysfunction and endothelial impairment to cognitive decline. *Exp Gerontol* 94:52-58. doi:10.1016/j.exger.2016.11.004
134. Terry RD (2000) Cell death or synaptic loss in Alzheimer disease. *J Neuropathol Exp Neurol* 59:1118-1119
135. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R (1991) Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. *Ann Neurol* 30:572-580. doi:10.1002/ana.410300410
136. Tong X, Ao Y, Faas GC, Nwaobi SE, Xu J, Haustein MD, Anderson MA, Mody I, Olsen ML, Sofroniew MV, Khakh BS (2014) Astrocyte K_{ir}4.1 ion channel deficits contribute to neuronal dysfunction in Huntington's disease model mice. *Nat Neurosci* 17:694-703. doi:10.1038/nn.3691
137. Valori CF, Guidotti G, Brambilla L, Rossi D (2019) Astrocytes: Emerging Therapeutic Targets in Neurological Disorders. *Trends Mol Med.* doi:10.1016/j.molmed.2019.04.010
138. Valtcheva S, Venance L (2019) Control of Long-Term Plasticity by Glutamate Transporters. *Front Synaptic Neurosci* 11:10. doi:10.3389/fnsyn.2019.00010

139. Verkhratsky A, Butt AM (2013) Glial Physiology and Pathophysiology. Wiley-Blackwell, Chichester
140. Verkhratsky A, Butt AM (2018) The History of the Decline and Fall of the Glial Numbers Legend. *Neuroglia* 1:188 - 192. doi:10.3390/neuroglia1010013
141. Verkhratsky A, Marutle A, Rodriguez-Arellano JJ, Nordberg A (2015) Glial asthenia and functional paralysis: A new perspective on neurodegeneration and Alzheimer's disease. *Neuroscientist* 21:552-568. doi:10.1177/1073858414547132
142. Verkhratsky A, Nedergaard M (2014) Astroglial cradle in the life of the synapse. *Philos Trans R Soc Lond B Biol Sci* 369:20130595. doi:10.1098/rstb.2013.0595
143. Verkhratsky A, Nedergaard M (2016) The homeostatic astroglia emerges from evolutionary specialization of neural cells. *Philos Trans R Soc Lond B Biol Sci* 371. doi:10.1098/rstb.2015.0428
144. Verkhratsky A, Nedergaard M (2018) Physiology of Astroglia. *Physiol Rev* 98:239-389. doi:10.1152/physrev.00042.2016
145. Verkhratsky A, Olabarria M, Noristani HN, Yeh CY, Rodriguez JJ (2010) Astrocytes in Alzheimer's disease. *Neurotherapeutics* 7:399-412. doi:10.1016/j.nurt.2010.05.017
146. Verkhratsky A, Parpura V (2016) Astrogliopathology in neurological, neurodevelopmental and psychiatric disorders. *Neurobiol Dis* 85:254-261. doi:10.1016/j.nbd.2015.03.025
147. Verkhratsky A, Parpura V, Rodriguez JJ (2011) Where the thoughts dwell: the physiology of neuronal-glia "diffuse neural net". *Brain Res Rev* 66:133-151. doi:10.1016/j.brainresrev.2010.05.002
148. Verkhratsky A, Rodriguez JJ, Parpura V (2012) Calcium signalling in astroglia. *Mol Cell Endocrinol* 353:45-56. doi:10.1016/j.mce.2011.08.039
149. Verkhratsky A, Rodriguez JJ, Steardo L (2014) Astrogliopathology: a central element of neuropsychiatric diseases? *Neuroscientist* 20:576-588. doi:10.1177/1073858413510208
150. Verkhratsky A, Sofroniew MV, Messing A, deLanerolle NC, Rempe D, Rodriguez JJ, Nedergaard M (2012) Neurological diseases as primary gliopathies: a reassessment of neurocentrism. *ASN Neuro* 4. doi:10.1042/AN20120010
151. Verkhratsky A, Zorec R, Parpura V (2017) Stratification of astrocytes in healthy and diseased brain. *Brain Pathol* 27:629-644. doi:10.1111/bpa.12537
152. Verkhratsky A, Zorec R, Rodriguez JJ, Parpura V (2016) Astroglia dynamics in ageing and Alzheimer's disease. *Curr Opin Pharmacol* 26:74-79. doi:10.1016/j.coph.2015.09.011
153. Virchow R (1858) Die Cellularpathologie in ihrer Begründung auf physiologische and pathologische Gewebelehre. Zwanzig Vorlesungen gehalten während der Monate Februar, März und April 1858 im pathologischen Institut zu Berlin. First edition edn. August Hirschwald, Berlin
154. Wakida NM, Cruz GMS, Ro CC, Moncada EG, Khatibzadeh N, Flanagan LA, Berns MW (2018) Phagocytic response of astrocytes to damaged neighboring cells. *PLoS One* 13:e0196153. doi:10.1371/journal.pone.0196153
155. Wallraff A, Kohling R, Heinemann U, Theis M, Willecke K, Steinhauser C (2006) The impact of astrocytic gap junctional coupling on potassium buffering in the hippocampus. *J Neurosci* 26:5438-5447. doi:10.1523/JNEUROSCI.0037-06.2006

156. Willis T (1672) *De Anima Brutorum quae Hominis Vitalis ac Sensitiva est. E Theatro Sheldoniano*; Ric.Davis Oxonii (Oxford)
157. Wu Z, Guo Z, Gearing M, Chen G (2014) Tonic inhibition in dentate gyrus impairs long-term potentiation and memory in an Alzheimer's [corrected] disease model. *Nat Commun* 5:4159. doi:10.1038/ncomms5159
158. Yamaguchi H, Sugihara S, Ogawa A, Saido TC, Ihara Y (1998) Diffuse plaques associated with astroglial amyloid beta protein, possibly showing a disappearing stage of senile plaques. *Acta Neuropathol* 95:217-222
159. Yamanaka K, Chun SJ, Boillee S, Fujimori-Tonou N, Yamashita H, Gutmann DH, Takahashi R, Misawa H, Cleveland DW (2008) Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. *Nat Neurosci* 11:251-253
160. Yamanaka K, Komine O (2018) The multi-dimensional roles of astrocytes in ALS. *Neurosci Res* 126:31-38. doi:10.1016/j.neures.2017.09.011
161. Yeh CY, Vadhvana B, Verkhratsky A, Rodriguez JJ (2012) Early astrocytic atrophy in the entorhinal cortex of a triple transgenic animal model of Alzheimer's disease. *ASN Neuro* 3:271-279. doi:10.1042/AN20110025
162. Yi C, Koulakoff A, Giaume C (2017) Astroglial Connexins as a Therapeutic Target for Alzheimer's Disease. *Curr Pharm Des* 23:4958-4968. doi:10.2174/1381612823666171004151215
163. Zeidan-Chulia F, Salmina AB, Malinovskaya NA, Noda M, Verkhratsky A, Moreira JC (2014) The glial perspective of autism spectrum disorders. *Neurosci Biobehav Rev* 38:160-172. doi:10.1016/j.neubiorev.2013.11.008
164. Zhao Y, Lin Z, Chen L, Ouyang L, Gu L, Chen F, Zhang Q (2018) Hippocampal astrocyte atrophy in a mouse depression model induced by corticosterone is reversed by fluoxetine instead of benzodiazepine diazepam. *Prog Neuropsychopharmacol Biol Psychiatry* 83:99-109. doi:10.1016/j.pnpbp.2018.01.011
165. Zonta M, Angulo MC, Gobbo S, Rosengarten B, Hossmann KA, Pozzan T, Carmignoto G (2003) Neuron-to-astrocyte signaling is central to the dynamic control of brain microcirculation. *Nat Neurosci* 6:43-50. doi:10.1038/nn980
166. Zorec R, Parpura V, Vardjan N, Verkhratsky A (2017) Astrocytic face of Alzheimer's disease. *Behav Brain Res* 322:250-257. doi:10.1016/j.bbr.2016.05.021

Figure legends

Figure 1. Diversity of astrocytes.

Figure 2. Classification of astrogliopathology. Modified from [103].

Figure 3. Astroglia atrophy in hippocampal (a) and cortical (B) regions of the wild type (WT) and triple transgenic AD model mouse (3xTG-AD). The images show GFAP-positive profiles of astroglial cells. Collated from [73,97,161].

Figure 4. Astrocytes derived from iPSCs isolated from familial AD patient carrying *PSEN1* M146L mutation and sporadic AD patient carrying *ApoE4*^{+/+} demonstrate significant atrophy when compared to those from healthy person.

(A) Morphological appearance (arborised, polarised and fibroblast-like) of astrocytes derived from iPSCs of healthy controls, familial and sporadic AD (FAD and SAD respectively). (B). Exemplar 3D IsoSurface renders constructed from serial confocal z-stacks display clear differences in cell size and overall morphology Scale bar = 10 μ m. Quantification of cells using these renders by way of surface area (C), cell volume (D) and SA:Vol ratio (E) reveal significant differences in all aspects of cellular morphology between healthy and diseased astrocytes. Quantification of mean fluorescence intensity per immunoreactive cell reveals no significant difference in GFAP staining intensities between AD- and control astrocytes (F) but S100B, EAAT1 and GS intensities are reduced in both FAD and SAD cells (G, H and I, respectively). Asterisks on graph; *** $p < 0.001$, ** $p < 0.005$, * $p < 0.05$. Reproduced from [60].

Table 1. Astrocytes in AD: Atrophy and loss of function

Model/Age/Preparation	Properties	Loss of function	Reference
5xFAD/12 - 14 months/ Primary culture		Reduced β -amyloid ₄₂ uptake; reduced neuroprotection reduced ability to promote neuronal growth	[58]
3xTG/ 4 Month/Fixed brain slices/Immunocytochemistry	Reduced morphological profiles and arborization	Treatment with L-norvaline rescued astroglial atrophy, increased dendritic spines densities and improved memory deficits	[107]
Swiss mice/ 3 month/Intracerebroventricular injection of 10 pM β -amyloid oligomers/immunocytochemistry	Morphological atrophy of astrocytes; ~23% reduction in a number of processes and ~40% reduction in surface area.	Decreased neuroprotection; increase in synaptic loss; both effects ameliorated by intracerebroventricular injection of 10 ng transforming growth factor- β 1	[32]
PDAPP-J20 mice/5 months/Immunocytochemistry	Decreased volume and complexity of hippocampal astrocytes		[8]
3xTG AD mice/1 to 24 months/Immunocytochemistry	Decreased volume, surface area and complexity of astrocytes in entorhinal and prefrontal cortices and in the hippocampus.	Loss of homoeostatic support	[73,97,98,161]

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Ref.: Ms. No. PAEJ-D-19-00142
Astroglial atrophy in Alzheimer's disease
Pflügers Archiv - European Journal of Physiology

Responses to reviewer's comments

Reviewer #1:

In their manuscript, the authors acknowledged the growing evidence that glial cells are not only affected by neurodegenerative processes, but are causative for neurodegeneration in diseases such as Alzheimer's. The authors are well-known experts in the field. The composition of the manuscript is reasonable and the selected literature well-balanced. However, there are many minor points, mainly addressing spelling, grammar and style, some of which are listed below. Therefore, I recommend a thorough check of the text.

Our reply: Thank you very much for constructive comments; we incorporated all your suggestions.

1) Many commas are missing.

Our reply: we proof read the text in particular from commas angle

2) P. 3, l. 18: Delete "n" in "Alzheimer's"

Our reply: Done

3) P. 3, l. 44: Delete one "single night" in "Even acute single night of sleep deprivation for a single night causes ..."

Our reply: Done

4) P. 5, l. 1: Change "reach" to "rich"

Our reply: Done

5) P. 6, l. 19: It is not clear what "disease- and disease-stage" means. The phrase appears to be incomplete.

Our reply: Thank you we meant "disease- and disease-stage specific"; the text is amended

6) P. 6, l. 20: Reconsider the sentence and the numbering of "Conceptually, astrogliopathological phenotypes are classified into three major groups: (i) reactive astrogliosis (ii) astrodegeneration with astroglial atrophy and loss of function; (ii) pathological remodelling"

Our reply: Done

7) P. 8, l. 57: The parenthesis is not closed in "(Table 1, [53,92,29,7]."

Our reply: Done

8) P. 9, l. 4: Change "AD mice model" in "AD mouse models"

Our reply: Done

9) P. 9, l. 8: Delete "s" in "signals"

Our reply: Done

10) P. 9, l. 49: Change "stem cells derived astrocytes" in "stem cell-derived astrocytes"

Our reply: Done

11) P. 10, l. 50: Lower case "p" in "Positron-emission"

Our reply: Done

12) P. 11, l. 7: Change "In recent decade" either in "In the recent decade" or in "In recent decades"

Our reply: Done

13) P. 11, l. 9: Change "patomorphological" in "pathomorphological"

Our reply: Done

14) P. 11, l. 16: "Alzheimer" to "Alzheimer's"

Our reply: Done

15) Fig. 3, legend: Add "A" and "B" to the legend.

Our reply: Done

16) Fig. 4. Panel A is not correctly explained in the legend. "(A)" actually refers to panel B. Information referring to panel A is missing.

Our reply: Done

17) Fig. 4. "Scale bar = 10 um". there is no scale bar in the figure.

Our reply: it was actually - but too thin, and made it ticker.

Reviewer #2:

Verkhatsky and co-authors provide an up-to-date and timely review focusing on the changes in astrocytes in neurodegenerative (and Alzheimer's) disease, which will be very valuable to the broad readership of Pfluegers Archive. The historical views and broad introduction are informative and these days neglected by most authors. My comments to the abstract reflect my most important concerns; the authors should make an effort to better clarify the topic of astrogliopathy versus different from of astrogliosis that in are discussed throughout the text.

Our reply: Thank you very much for constructive comments; we incorporated your suggestions.

1. Abstract: several terms are used which are not clearly defined. Reactive gliosis is generally viewed as being accompanied by hypertrophy of astrocytes, the latter mostly referring to the increase in GFAP expression and increased thickness of primary processes. What then is meant by "hypotrophy"? The same is true for the terms "astrogliosis"/"astrogliotic response"/"astrogliial hypotrophy / atrophy / paralysis". The abstract would greatly profit from a clear definition and separation of these terms. Alternatively, these terms should be omitted and more general summarizing statements be made in the abstract.

Our reply: We edited the abstract; obviously the word "hypotrophy" was a typo; astrogliosis is indeed characterised by hypertrophic changes.

As to terminology: (i) Astrogliosis; (ii) Astroglial atrophy and (iii) Pathological remodelling of astrocytes - this has been defined in several recent publications and are quite generally accepted (see consensus paper by Pekny M et al. (2016) Astrocytes: a central element in neurological diseases. *Acta Neuropathol* 131:323-345 doi:10.1007/s00401-015-1513-1; and recent essay by us Verkhatsky A, Zorec R, Parpura V (2017) Stratification of astrocytes in healthy and diseased brain. *Brain Pathol* 27:629-644 doi:10.1111/bpa.12537). To make this terminology easy for a reader we have now included a text box with a glossary of the terms.

2. There is a lot of evidence showing that astrocytes are not just "homeostatic" cells but actively contribute to brain communication.

Our reply: We fully agree that astrocytes communicate with other brain cells through numerous mechanisms; all their homeostatic cascades are “active” and do affect neurones and synapses. We have discussed these matters in depth in previous publications (e.g. *Physiol Rev* 2018).

3. Page3, line 59: what is meant by "compromised synaptic physiology"; isn't hyperexcitability always "aberrant"?

Our reply: we agree and we amended the text accordingly

4. Page 4, lines 1-7: white matter (oligodendrocyte) damage is probably not primarily associated with failure in homeostatic neuroglia, which, in the context of the review here, relates to astrocytes?

Our reply: Oligodendrocytes are as homeostatic as astrocytes in white matter - they support axons in many ways including for example supplying them with lactate. In this context we simply mentioned that oligodendrodegeneration (which is rather prominent in AD) contributes to overall “unwiring” of the brain.

5. The term "homeostasis/homeostatic" is used quite often throughout the text. What exactly is meant by that? It is used as if "homeostasis" is the ultimate goal and ultimate condition to attain. Life as such is probably never in a "homeostatic" condition.

Our reply: this is of course very interesting and philosophical question; we as such are following the ideas of Claude Bernard, Walter Cannon and Joseph Barcroft. Failure in physiological homeostasis means disease and inability of the organism to maintain physiological homeostasis leads to extinction of biological entity; failure of homeostatic control of brain tissue signals its inability to perform - i.e. dementia in the broadest reading of it.

6. Page 5, line 28: There is no clear evidence that "neurological disorders are the failure of tissue homeostasis". This is a rather general statement and as such, debatable. What is meant by tissue homeostasis?

Our reply: This is how we define the disease: disease is failure of homeostatic systems which are unable anymore to maintain structural and functional stability. This definition is obviously open to debate, which we of course welcome. We agree however that the word “tissue” is inappropriate in this context and we amended the text accordingly.

7. Page 6, lines 16: Neurones can well survive without glia, this is the basis for primary neuronal cell cultures...

Our reply: well, purified cultures of central neurones (i.e. without astrocytes) do not thrive and form much less synapses; at the organism level ablation of glia is lethal for

neurones.

8. Pages 3-6: the text somewhat jumps back and forth, addressing properties of astrocytes and their arrangement in networks, as well as their physiological roles in healthy tissue and then mentioning changes in response to different pathologies. The review would greatly profit from a more organized separation of topics to discuss: e.g. first describe astrocytes and their function /organization in the healthy brain, and only then describe astrocytes under different pathological conditions.

Our reply: this is the matter of opinion: we feel that we did exactly what is proposed by the reviewer.

9. Page 6/7 and following: it is clearly debatable that reactive gliosis is a purely defensive programme. Reactive astrocytes reduce their "homeostatic" functions and have been reported to "de-differentiate", including a reduced expression of glutamate transporters, KIR-channels, NKA, gap junction coupling. Increased expression of GFAP should be mentioned, as well as changes in their morphology, retraction of processes This, however, is described only later (page 7), and referred to as "astrodegeneration". Again, it seems mandatory, that the different terms used ("reactive astrogliosis", "astrodegeneration", "astrotrophy",...) are better defined. Glial scar formation, involving reactive gliosis and proliferation of astrocytes must be separated from "hypertrophy" and "astrotrophy".

Our reply: we are somewhat confused by this logic. We of course agree that astroglial reactivity may produce neurotoxic phenotypes and we state that ("Being driven to an extreme by the severity of the insult, glial cells can assume the role of natural killer and contribute to the neural cell death, and yet even neurotoxicity of glia has, at its core, neuroprotective significance. "; our argument is rather simple - evolution never selects for negative mechanisms only for positive or neutral; hence astroglial neurotoxicity has at its core some beneficial effects - e.g. elimination of compromised neurones which may help faster resolution of pathology. The scar is obviously defensive, this seems rather obvious - a making a wall between healthy and damaged tissues.; of course if driven out of balance neurotoxic phenotypes facilitates cell death and overall demise of tissue which we clearly acknowledged. We do not use term "astrotrophy"? The terms "atrophy" and loss of function which we employ are of very general usage in medical literature. Now we have introduced a glossary to clearly define these.

10. Page 9, lines 38 ff: reactive astrocyte near lesions are characterized by aberrant calcium handling, which should be discussed.

Our reply: We fully agree with this; and yet in this paper we do not discuss much astroglial reactivity in AD; this has been covered by many excellent reviews; we specifically focus on astroglial atrophy, and hence this discussion is, in our opinion, outside of the scope.

11. Page 9, lines 54/55: the consequences of a retraction of astrocyte processes from synapses are not clear. Retraction of glial processes might also cause a widening of the ECS and a "dilution" of glutamate that escapes the synaptic cleft.

Our reply: In fact the main consequence of astroglial process retraction would be removal of glutamate transporters from the synapse. Indeed enhanced spillover obviously causes aberrant synaptic transmission - and weakens synaptic potentiation - this is exactly our logic.

12. Page 10, lines 8/9: reduction of glutamate uptake might be accompanied by desensitization of AMPA receptors.

Our reply: possibly yes however we are not aware about any data on this matter in the context of AD.

13. Page 10, line30: it is not clear from the text above, that astrogliosis is a "powerful defensive programme". The examples mentioned later show, at best, a correlation between astrocyte gliosis, amyloid deposition, and AD. At present, this seems rather like a "chicken and egg" problem, which should be acknowledged.

Our reply: we politely disagree; again this are all matters of opinion and writing style.

14. Fig. 1: the direct line between "specialized astrocytes" and "Human astrocytes" does not make sense.

Our reply: Thank you, we amended a figure accordingly

15. Fig. 2: should be revised and then could help in clarifying the different expressions used (see comments above). The term "astrogliopathology" somewhat bears the notion that astrocytes degenerate themselves. Reactive astrocytes are e.g. also observed during healthy ageing, is this pathological already? Again, please define what is mean by reactive astrogliosis and include all other terms used in the text.

Our reply: This figure shows classification of pathological changes which has been explained in detail in previous papers, which is of course fully acknowledged - this figure is take from Pekny et al., Acta Neuropathol, 2016. We do not call anywhere reactive astrocytes "pathological"; and yes astrocytes do degenerate by themselves in many neurological diseases; all this has been covered previously and we see no reason in repeating this here. We added the Glossary of terms to the text.

16. Fig. 3: apparently shows GFAP-labelling? Please state in the legend. GFAP does not delineate the entire morphology of the cells.

Our reply: Thank you; and we modified figure legend and the text accordingly.

17. Fig. 4: needs further explanation in the legend as well. These are cells derived from iPSCs?

Our reply: Yes and we edited the figure legend

18. General: the text is clearly written, but many typos and grammatical errors remain (e.g. page 3, lines 8/9, should read: "processes"; line 10: "A direct link..."; ...). Please proofread carefully.

Our reply: we read the paper and amended many of those small typos - thank you.

Change of authorship request form (pre-acceptance)

Please read the important information on page 4 before you begin

This form should be used by authors to request any change in authorship including changes in corresponding authors. Please fully complete all sections. Use black ink and block capitals and provide each author’s full name with the given name first followed by the family name.

Please note: In author collaborations where there is formal agreement for representing the colla boration, it is sufficient for the representative or legal guarantor (usually the corresponding author) to complete and sign the Authorship Change Form on behalf of all authors.

Section 1: Please provide the current title of manuscript

(For journals: Please provide the manuscript ID, title and/or DOI if available.)

(For books: Please provide the title, ISBN and/or DOI if available.)

Manuscript ID no. in case of unpublished manuscript: PAEJ-D-19-00142R1
DOI in case of published manuscript:
ISBN (for books):

Title:	Astroglial atrophy in Alzheimer's disease
--------	---

Section 2: Please provide the previous authorship, in the order shown on the manuscript before the changes were introduced. Please indicate the corresponding author by adding (CA) behind the name.

	First name(s)	Family name	ORCID or SCOPUS id, if available
1 st author	Alexei	Verkh ratsky CA	
2 nd author	Jose Julio	Rodriguez	
3 rd author	Robert	Zorec	
4 th author	Alexey	Semyanov	
5 th author			
6 th author			
7 th author			

Please use an additional sheet if there are more than 7 authors.

Section 3: Please provide a justification for change. Please use this section to explain your reasons for changing the authorship of your manuscript, e.g. what necessitated the change in authorship? Please refer to the (journal) policy pages for more information about authorship. Please explain why omitted authors were not originally included and/or why authors were removed on the submitted manuscript.

Section 4: Proposed new authorship. Please provide your new authorship list in the order you would like it to appear on the manuscript. Please indicate the corresponding author by adding (CA) behind the name. If the corresponding author has changed, please indicate the reason under section 3.

	First name(s)	Family name (this name will appear in full on the final publication and will be searchable in various abstract and indexing databases)
1 st author	Alexei	Verkh ratsky CA
2 nd author	Jose Julio	Rodriguez
3 rd author	Augustas	Pivoriunas
4 th author	Robert	Zorec
5 th author	Alexey	Semyanov
6 th author		
7 th author		

Please use an additional sheet if there are more than 7 authors.

Change of authorship request form (pre-acceptance)

Section 5: Author contribution, Acknowledgement and Disclosures. Please use this section to provide a new disclosure statement and, if appropriate, acknowledge any contributors who have been removed as authors and ensure you state what contribution any new authors made (if applicable per the journal or book (series) policy). **Please ensure these are updated in your manuscript - after approval of the change(s) - as our production department will not transfer the information in this form to your manuscript.**

New acknowledgements:	
N/A	
New Disclosures (financial and non-financial interests, funding):	
N/A	
New Author Contributions statement (if applicable per the journal policy):	
N/A	

State 'Not applicable' if there are no new authors.

Change of authorship request form (pre-acceptance)

Section 6: Declaration of agreement. All authors, unchanged, new and removed *must* sign this declaration.

(NB: Please print the form, sign and return a scanned copy. Please note that signatures that have been inserted as an image file are acceptable as long as it is handwritten. Typed names in the signature box are unacceptable.) * Please delete as appropriate. Delete all of the bold if you were on the original authorship list and are remaining as an author.

	First name	Family name	I agree to the proposed new authorship shown in section 4 /and the addition/removal* of my name to the authorship list.	Signature	Affiliated institute	Date
1 st author	Alexei	Verkhatsky CA	I agree to the proposed new authorship shown in section 4 /and the addition/removal* of my name to the authorship list.		The University of Manchester	Aug 22 2019
2 nd author	Jose Julio	Rodriguez	I agree to the proposed new authorship shown in section 4 /and the addition/removal* of my name to the authorship list.		The University of the Basque Country	Aug 22 2019
3 rd author	Augustas	Pivoriunas	I agree to the proposed new authorship shown in section 4 /and the addition/removal* of my name to the authorship list.		State Research Institute Centre for Innovative Medicine	Aug 22 2019
4 th authors	Robert	Zorec	I agree to the proposed new authorship shown in section 4 /and the addition/removal* of my name to the authorship list.		University of Ljubljana	Aug 22 2019
5 th author	Alexey	Semyanov	I agree to the proposed new authorship shown in section 4 /and the addition/removal* of my name to the authorship list.		Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry	Aug 22 2019
6 th author			I agree to the proposed new authorship shown in section 4 /and the addition/removal* of my name to the authorship list.			
7 th author			I agree to the proposed new authorship shown in section 4 /and the addition/removal* of my name to the authorship list.			

Please use an additional sheet if there are more than 7 authors.

Important information. Please read.

- Please return this form, fully completed, to Springer Nature. We will consider the information you have provided to decide whether to approve the proposed change in authorship. We may choose to contact your institution for more information or undertake a further investigation, if appropriate, before making a final decision.
- By signing this declaration, all authors guarantee that the order of the authors are in accordance with their scientific contribution, if applicable as different conventions apply per discipline, and that only authors have been added who made a meaningful contribution to the work.
- Please note, we cannot investigate or mediate any authorship disputes. If you are unable to obtain agreement from all authors (including those who you wish to be removed) you must refer the matter to your institution(s) for investigation. Please inform us if you need to do this.
- If you are not able to return a fully completed form within **30 days** of the date that it was sent to the author requesting the change, we may have to withdraw your manuscript. We cannot publish manuscripts where authorship has not been agreed by all authors (including those who have been removed).
- Incomplete forms will be rejected.

Fig. 1

Fig. 2

Fig. 3